News | April 18, 2014

Tendyne Raises $25 Million to Fund Transcatheter Mitral Valve

April 18, 2014 — Tendyne Holdings Inc. has secured $25 million in an oversubscribed Series C financing led by Apple Tree Partners, along with Boulle Group members and other existing investors. Proceeds will be used for validation of Tendyne's novel transcatheter mitral valve implant to treat mitral regurgitation, including forthcoming clinical trials.  

"This financing is a significant milestone for Tendyne. In 2013 Tendyne demonstrated positive human data and this infusion of capital allows us to move ahead confidently as we accelerate our minimally invasive mitral valve program," said Jeff Franco, founder and CEO of Tendyne. "We are excited to have Apple Tree Partners come on board. We look forward to benefiting from their experience as we develop our technology and clinical presence."

Formed in 2010, Tendyne's first product is a transcatheter mitral valve replacement prosthesis for the treatment of both functional and degenerative mitral regurgitation. Tendyne's mitral valve is deployed and secured while preserving the sub-valvular apparatus. The Tendyne valve will initially be implanted transapically in a simple procedure that allows the physician to re-position or retrieve the valve after full deployment.

David McIntyre, a partner at Apple Tree Partners, will join the Board of Directors at Tendyne.

For more information: www.tendyne.com

Related Content

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology| January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology| January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology| November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology| November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Videos | Heart Valve Technology| November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Harpoon Mitral Valve Repair System data reported at TCT 2017
Feature | Heart Valve Technology| November 07, 2017
November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and c
Videos | Heart Valve Technology| November 07, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state o
Overlay Init